Envestnet Asset Management’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Envestnet Asset Management’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-31,086	Closed	-$1.34M	–	3153
2015 Q3	$1.34M	Buy	31,086 +4,430	+17%	+$187K	0.01%	1128
2015 Q2	$1.13M	Buy	26,656 +5,351	+25%	+$226K	0.01%	1345
2015 Q1	$826K	Buy	21,305 +20,439	+2,360%	+$787K	﹤0.01%	1366
2014 Q4	$29K	Buy	866 +46	+6%	+$1.63K	﹤0.01%	1630
2014 Q3	$29K	Sell	820 -519	-39%	-$17.8K	﹤0.01%	1742
2014 Q2	$44K	Sell	1,339 -693	-34%	-$23.7K	﹤0.01%	1487
2014 Q1	$75K	Buy	2,032 +157	+8%	+$5.76K	﹤0.01%	1233
2013 Q4	$72K	Buy	1,875 +1,493	+391%	+$47.1K	﹤0.01%	1116
2013 Q3	$10K	Buy	382 +291	+320%	+$6.89K	﹤0.01%	1723
2013 Q2	$2K	Buy	+91	New	+$1.78K	﹤0.01%	2150

Other funds holding WX

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

CCS

Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Envestnet Asset Management's WX Position: Q4 2015 in Review

Envestnet Asset Management sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 31,086 shares — an estimated $1.34M sold.

Envestnet Asset Management first reported a position in WX in Q2 2013 and held it in 10 quarters. The position peaked at $1.34M in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

Envestnet Asset Management reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
Envestnet Asset Management sold 31,086 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $1.34M.
Envestnet Asset Management first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 10 quarters.
Envestnet Asset Management's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $1.34M in Q3 2015.
2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Envestnet Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.